Subtopic Deep Dive
Cardiac Transthyretin Amyloidosis Imaging
Research Guide
What is Cardiac Transthyretin Amyloidosis Imaging?
Cardiac Transthyretin Amyloidosis Imaging uses nuclear scintigraphy, cardiac MRI, and echocardiography for non-invasive diagnosis of ATTR amyloid cardiomyopathy.
Technetium-99m-labeled bone-seeking tracers like DPD and PYP detect cardiac ATTR amyloid deposits with high sensitivity (Gillmore et al., 2016; 1894 citations). These methods enable non-biopsy diagnosis when combined with biomarkers, avoiding invasive procedures (Hutt et al., 2014; 240 citations). Over 50 papers since 2014 document imaging protocols and outcomes in ATTR-CM.
Why It Matters
Non-biopsy imaging with 99mTc-PYP scintigraphy identifies ATTR-CM in HFpEF patients, enabling tafamidis treatment that reduces mortality and hospitalizations (Maurer et al., 2018; 2523 citations). Prevalence studies show ATTR-CM in 13-16% of elderly HFpEF with hypertrophy, improving prognosis via early therapy (AbouEzzeddine et al., 2021; 177 citations). Algorithms combining scintigraphy grades and biomarkers guide therapy in aortic stenosis comorbidities (Nitsche et al., 2020; 338 citations).
Key Research Challenges
Scintigraphy Specificity Limits
Bone tracers like 99mTc-DPD show high sensitivity but require biomarkers to distinguish ATTR from AL amyloidosis (Hutt et al., 2014). False positives occur in non-ATTR conditions without monoclonal protein exclusion (Hanna et al., 2020). Standardization of uptake grading (Perugini scale) varies across centers.
Mutation-Specific Low Sensitivity
99mTc-bone scintigraphy misses cardiac involvement in Phe64Leu ATTR mutations despite hypertrophy (Musumeci et al., 2019; 149 citations). Early detection fails before echocardiographic changes (Glaudemans et al., 2014). Genetic testing complements imaging in familial cases.
Comorbid Disease Differentiation
ATTR-CM overlaps with aortic stenosis, delaying diagnosis without multi-modality imaging (Nitsche et al., 2020). Echocardiography lacks specificity for amyloid vs. hypertrophy (Gillmore et al., 2016). Prognostic scoring integrates MRI with scintigraphy for risk stratification.
Essential Papers
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Matthew J. Maurer, Jeffrey H. Schwartz, Balarama Gundapaneni et al. · 2018 · New England Journal of Medicine · 2.5K citations
In patients with transthyretin amyloid cardiomyopathy, tafamidis was associated with reductions in all-cause mortality and cardiovascular-related hospitalizations and reduced the decline in functio...
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Julian D. Gillmore, Matthew J. Maurer, Rodney H. Falk et al. · 2016 · Circulation · 1.9K citations
Background— Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal cardiomyopathy for which several promising therapies are in development. The diagnosis is frequently delayed or misse...
Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis
Christian Nitsche, Paul Scully, Kush Patel et al. · 2020 · Journal of the American College of Cardiology · 338 citations
Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis
David F. Hutt, Anne‐Marie Quigley, Joanne Page et al. · 2014 · European Heart Journal - Cardiovascular Imaging · 240 citations
(99m)Tc-DPD scintigraphy is a highly sensitive technique for imaging cardiac ATTR amyloidosis and is an important investigation in the diagnostic pathway of patients with cardiac amyloidosis. It is...
Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis
Mazen Hanna, Frederick L. Ruberg, Matthew J. Maurer et al. · 2020 · Journal of the American College of Cardiology · 226 citations
Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction
Omar F. AbouEzzeddine, Daniel R. Davies, Christopher G. Scott et al. · 2021 · JAMA Cardiology · 177 citations
In this cohort study based in a community-based setting, ATTR-CM was present in a substantial number of cases of HFpEF with ventricular wall thickening, particularly in older men. These results sug...
Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis
Beatrice Musumeci, Francesco Cappelli, Domitilla Russo et al. · 2019 · JACC. Cardiovascular imaging · 149 citations
Reading Guide
Foundational Papers
Start with Hutt et al. (2014; 240 citations) for DPD scintigraphy validation and Glaudemans et al. (2014; 145 citations) for early ATTR detection, as they define nuclear imaging protocols cited in all modern algorithms.
Recent Advances
Study Gillmore et al. (2016; 1894 citations) for non-biopsy diagnosis, Maurer et al. (2018; 2523 citations) for treatment links, and AbouEzzeddine et al. (2021; 177 citations) for HFpEF prevalence.
Core Methods
Core techniques: 99mTc-DPD/PYP scintigraphy (Perugini grading), cardiac MRI (T1 mapping/ECV), echocardiography (strain imaging); combined in algorithms excluding monoclonal proteins (Gillmore et al., 2016).
How PapersFlow Helps You Research Cardiac Transthyretin Amyloidosis Imaging
Discover & Search
Research Agent uses searchPapers('Cardiac Transthyretin Amyloidosis scintigraphy') to retrieve 50+ papers including Gillmore et al. (2016), then citationGraph reveals forward citations on tafamidis outcomes (Maurer et al., 2018) and exaSearch uncovers prevalence in HFpEF (AbouEzzeddine et al., 2021). findSimilarPapers expands to mutation-specific limitations.
Analyze & Verify
Analysis Agent applies readPaperContent on Hutt et al. (2014) to extract DPD grading protocols, verifyResponse with CoVe checks scintigraphy specificity claims against Gillmore et al. (2016), and runPythonAnalysis computes meta-analysis of sensitivity (NumPy/pandas on 10 papers' AUC values). GRADE grading scores non-biopsy algorithm evidence as high-quality.
Synthesize & Write
Synthesis Agent detects gaps in mutation imaging via contradiction flagging between Musumeci et al. (2019) and standard protocols, then Writing Agent uses latexEditText for diagnostic flowcharts, latexSyncCitations for 20-paper bibliography, and latexCompile for review manuscript. exportMermaid generates Perugini scintigraphy grade diagrams.
Use Cases
"Extract scintigraphy sensitivity data from top ATTR-CM papers and compute pooled AUC"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Gillmore 2016, Hutt 2014) → runPythonAnalysis (pandas meta-analysis plot) → researcher gets CSV of pooled 95% CI and matplotlib ROC curve.
"Draft LaTeX review on non-biopsy ATTR diagnosis algorithm"
Synthesis Agent → gap detection → Writing Agent → latexGenerateFigure (flowchart) → latexSyncCitations (Maurer 2018 et al.) → latexCompile → researcher gets PDF with embedded citations and diagrams.
"Find GitHub code for ATTR scintigraphy grading AI models"
Research Agent → paperExtractUrls (Hanna 2020) → paperFindGithubRepo → githubRepoInspect → researcher gets repo with PyTorch uptake quantification script and training data.
Automated Workflows
Deep Research workflow scans 50+ papers on ATTR imaging, chains searchPapers → citationGraph → GRADE summary report on diagnostic accuracy. DeepScan's 7-steps verify scintigraphy protocols with CoVe checkpoints on Hutt (2014) vs. Hanna (2020). Theorizer generates hypotheses on tafamidis response predictors from Maurer (2018) imaging subsets.
Frequently Asked Questions
What defines Cardiac Transthyretin Amyloidosis Imaging?
It employs 99mTc-DPD/PYP scintigraphy, MRI, and echo for non-invasive ATTR-CM detection, graded by heart uptake (Perugini 0-3) without biopsy (Gillmore et al., 2016).
What are key imaging methods?
99mTc-bone tracers detect ATTR deposits (Hutt et al., 2014; sensitivity >90%), combined with NT-proBNP/ troponin for specificity; MRI quantifies extracellular volume (Fontana et al., 2019).
What are seminal papers?
Gillmore et al. (2016; 1894 citations) established non-biopsy criteria; Maurer et al. (2018; 2523 citations) linked imaging to tafamidis outcomes; Hutt et al. (2014; 240 citations) validated DPD utility.
What open problems remain?
Low scintigraphy sensitivity in rare mutations (Musumeci et al., 2019); comorbid AS differentiation (Nitsche et al., 2020); quantitative MRI prognostic scores beyond visual grading.
Research Medical Imaging and Pathology Studies with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Cardiac Transthyretin Amyloidosis Imaging with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.